These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35576438)

  • 1. Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial.
    Lee CH; Motzer R; Emamekhoo H; Matrana M; Percent I; Hsieh JJ; Hussain A; Vaishampayan U; Liu S; McCune S; Patel V; Shaheen M; Bendell J; Fan AC; Gartrell BA; Goodman OB; Nikolinakos PG; Kalebasty AR; Zakharia Y; Zhang Z; Parmar H; Akella L; Orford K; Tannir NM
    Clin Cancer Res; 2022 Aug; 28(15):3248-3255. PubMed ID: 35576438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.
    Tannir NM; Agarwal N; Porta C; Lawrence NJ; Motzer R; McGregor B; Lee RJ; Jain RK; Davis N; Appleman LJ; Goodman O; Stadler WM; Gandhi S; Geynisman DM; Iacovelli R; Mellado B; Sepúlveda Sánchez JM; Figlin R; Powles T; Akella L; Orford K; Escudier B
    JAMA Oncol; 2022 Oct; 8(10):1411-1418. PubMed ID: 36048457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial.
    Meric-Bernstam F; Tannir NM; Iliopoulos O; Lee RJ; Telli ML; Fan AC; DeMichele A; Haas NB; Patel MR; Harding JJ; Voss MH; Owonikoko TK; Carthon B; Srinivasan R; Bendell JC; Jenkins Y; Whiting SH; Orford K; Bennett MK; Bauer TM
    Clin Cancer Res; 2022 Apr; 28(8):1540-1548. PubMed ID: 35140121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
    Emberley E; Pan A; Chen J; Dang R; Gross M; Huang T; Li W; MacKinnon A; Singh D; Sotirovska N; Steggerda SM; Wang T; Parlati F
    PLoS One; 2021; 16(11):e0259241. PubMed ID: 34731180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study.
    Guo J; Huang Y; Zhang X; Zhou F; Sun Y; Qin S; Ye Z; Wang H; Jappe A; Straub P; Pirotta N; Gogov S
    BMC Cancer; 2013 Mar; 13():136. PubMed ID: 23514360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.
    Wiele AJ; Bathala TK; Hahn AW; Xiao L; Duran M; Ross JA; Jonasch E; Shah AY; Campbell MT; Msaouel P; Tannir NM
    Oncologist; 2021 Jun; 26(6):476-482. PubMed ID: 33792094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
    Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J
    BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.
    Calvo E; Escudier B; Motzer RJ; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Ravaud A; Kim D; Panneerselvam A; Anak O; Figlin RA
    Eur J Cancer; 2012 Feb; 48(3):333-9. PubMed ID: 22209391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
    Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
    Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
    Kato R; Obara W; Matsuura T; Kato Y; Iwasaki K; Fujioka T
    Jpn J Clin Oncol; 2014 May; 44(5):479-85. PubMed ID: 24688083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial.
    Porta C; Calvo E; Climent MA; Vaishampayan U; Osanto S; Ravaud A; Bracarda S; Hutson TE; Escudier B; Grünwald V; Kim D; Panneerselvam A; Anak O; Motzer RJ
    Eur Urol; 2012 Apr; 61(4):826-33. PubMed ID: 22297244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis.
    Bracarda S; Hutson TE; Porta C; Figlin RA; Calvo E; Grünwald V; Ravaud A; Motzer R; Kim D; Anak O; Panneerselvam A; Escudier B
    Br J Cancer; 2012 Apr; 106(9):1475-80. PubMed ID: 22441644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial.
    Staehler M; Stöckle M; Christoph DC; Stenzl A; Potthoff K; Grimm MO; Klein D; Harde J; Brüning F; Goebell PJ; Augustin M; Roos F; Benz-Rüd I; Marschner N; Grünwald V
    Int J Cancer; 2021 Apr; 148(7):1685-1694. PubMed ID: 33070307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.
    Thiery-Vuillemin A; Theodore C; Jacobasch L; Schmitz J; Papandreou C; Guillot A; Emmanouilides C; Slimane K; Kelkouli N; Kim S; Nguyen Tan Hon T
    Clin Genitourin Cancer; 2015 Jun; 13(3):231-8. PubMed ID: 25456838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.
    Motzer RJ; Escudier B; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Figlin RA; Hollaender N; Kay A; Ravaud A;
    Cancer; 2010 Sep; 116(18):4256-65. PubMed ID: 20549832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
    Choueiri TK; Escudier B; Powles T; Tannir NM; Mainwaring PN; Rini BI; Hammers HJ; Donskov F; Roth BJ; Peltola K; Lee JL; Heng DYC; Schmidinger M; Agarwal N; Sternberg CN; McDermott DF; Aftab DT; Hessel C; Scheffold C; Schwab G; Hutson TE; Pal S; Motzer RJ;
    Lancet Oncol; 2016 Jul; 17(7):917-927. PubMed ID: 27279544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: a registry-based analysis.
    Buchler T; Bortlicek Z; Poprach A; Kubackova K; Kiss I; Zemanova M; Fiala O; Dusek L; Vyzula R; Melichar B;
    Urol Oncol; 2014 Jul; 32(5):569-75. PubMed ID: 24629497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.
    Voss MH; Bhatt RS; Vogelzang NJ; Fishman M; Alter RS; Rini BI; Beck JT; Joshi M; Hauke R; Atkins MB; Burgess E; Logan TF; Shaffer D; Parikh R; Moazzam N; Zhang X; Glasser C; Sherman ML; Plimack ER
    Cancer; 2019 Jul; 125(14):2400-2408. PubMed ID: 30951193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
    Motzer RJ; Escudier B; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Figlin RA; Hollaender N; Urbanowitz G; Berg WJ; Kay A; Lebwohl D; Ravaud A;
    Lancet; 2008 Aug; 372(9637):449-56. PubMed ID: 18653228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study).
    Grünwald V; Hilser T; Meiler J; Goebell PJ; Ivanyi P; Strauss A; Hartmann A; Bedke J; Bergmann L
    Oncol Res Treat; 2022; 45(5):272-280. PubMed ID: 35045416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.